专题论文

癌症的精准医疗

  • 程旭东 ,
  • 蒋丽萍 ,
  • 毛凯晟
展开
  • 北京泛生子基因科技有限公司, 北京 102206
程旭东,博士,研究方向为癌症液态活检平台建设和相关检测技术开发,电子信箱:xudong.cheng@genetronhealth.com

收稿日期: 2016-08-30

  修回日期: 2016-10-11

  网络出版日期: 2016-11-05

Precision cancer medicine

  • CHENG Xudong ,
  • JIANG Liping ,
  • MAO Kaisheng
Expand
  • Genetron Health(Beijing) Co., Ltd., Beijing 102206, China

Received date: 2016-08-30

  Revised date: 2016-10-11

  Online published: 2016-11-05

摘要

随着基因组学、生物芯片、下一代测序、大数据云计算、人工智能、生物制药等新技术的综合运用及普及,精准医疗尤其是应用于癌症领域的精准医疗,正步入快速发展阶段。获取、分析和利用个性化的癌症基因组学数据,将成为癌症临床研究,尤其是新药研发的关键,这也同时突显出可靠的分子诊断检测平台的重要性。本文综述癌症精准医疗的定义与意义、发展历史与现状、关键技术、挑战与展望等,并举例说明脑胶质瘤和结直肠癌领域精准医疗的发展现状。

本文引用格式

程旭东 , 蒋丽萍 , 毛凯晟 . 癌症的精准医疗[J]. 科技导报, 2016 , 34(20) : 51 -55 . DOI: 10.3981/j.issn.1000-7857.2016.20.008

Abstract

Major technological advances and their popularization in the genomics, the bio-microarray, the next generation sequencing, the big data and the cloud computing, the artificial intelligence, the bio-pharmaceutical engineering make the precision medicine, especially, the precision medicine in curing the cancer step into a stage of exponential growth. Acquiring, analyzing and understanding the personal cancer genomics are the key in the process from the drug discovery to the novel designs of clinical trials, which also shows the critical importance of robust molecular diagnostics platforms. This paper gives an overview of the concept, the significance, the history, the techniques, the challenges and the prospects of the precision cancer medicine, as well as the applications of the precision medicine in the gliomas and colorectal cancer.

参考文献

[1] National Research Council:Committee on a Framework for Developing a New Taxonomy of Disease. Toward precision medicine:Building a knowledge net-work for biomedical research and a new taxonomy of disease[R]. Washington DC:National Academies Press, 2011.
[2] The White House. The precision medicine initiative[EB/OL].[2016-08-27]. https://www.whitehouse.gov/precision-medicine.
[3] Collins F S, Varmus H. A new initiative on precision medicine[J]. The New England Journal of Medicine, 2015, 372(9):793-795.
[4] The catalogue of somatic mutations in cancer[DB].[2016-08-27]. http://cancer.sanger.ac.uk/cosmic.
[5] The cancer genome atlas[DB].[2016-08-27]. https://tcgadata.nci.nih.gov/tcga.
[6] The cancer genome atlas[DB].[2016-08-27]. https://tcga-data.nci.nih.gov/docs/publications/tcga/?.
[7] International Cancer Genome Consortium. ICGC cancer genome project[EB/OL].[2016-08-27]. https://icgc.org/files/ICGC%20Brochure%20International%20December%202015%20v1%20-%20outer.jpg.
[8] Yan H, Parsons D W, Jin G L, et al. IDH1 and IDH2 mutations in gliomas[J]. The New England Journal of Medicine, 2009, 360(8):765-773.
[9] Killela P J, Reitman Z J, Jiao Y C, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal[J]. PNAS, 2013, 110(15):6021-6026.
[10] Zhang L, Chen L H, Wan H, et al. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas[J]. Nature Genetics, 2014, 46(7):726-730.
[11] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology:Central nervous system cancers, V.2.2014[EB/OL].[2016-08-27]. https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf.
[12] Jiang T, Mao Y, Ma W, et al. CGCG clinical practice guidelines for the management of adult diffuse gliomas[J]. Cancer Letters, 2016, 375(2):263-273.
[13] Le D T, Uram J N, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency[J]. The New England Journal of Medicine, 2015, 372(26):2509-2520.
[14] Dressman D, Yan H, Traverso G, et al. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations[J]. PNAS, 2003, 100(15):8817-8822.
[15] Tie J, Kinde I, Wang Y, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer[J]. Annals of Oncology Official Journal of the European Society for Medical Oncology, 2015, 26(8):1715.
[16] Tie J, Wang Y X, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage Ⅱ colon cancer[J]. Science Translational Medicine, 2016, 8:346.
[17] Frattini V, Trifonov V, Chan J M, et al. The integrated landscape of driver genomic alterations in glioblastoma[J]. Nature Genetics, 2013, 45(10):1141-1149.
[18] Pritchard C C, Mateo J, Walsh M F, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer[J]. The New England Journal of Medicine, 2016, 375(5):443-453.
[19] Illumina. Whole-genome sequencing power[EB/OL].[2016-08-27]. http://www.illumina.com/systems/hiseq-x-sequencing-system.html.
文章导航

/